279 related articles for article (PubMed ID: 31867793)
1. Towards an understanding of Angelman syndrome in mice studies.
Yang X
J Neurosci Res; 2020 Jun; 98(6):1162-1173. PubMed ID: 31867793
[TBL] [Abstract][Full Text] [Related]
2. Adult
Rotaru DC; van Woerden GM; Wallaard I; Elgersma Y
J Neurosci; 2018 Sep; 38(37):8011-8030. PubMed ID: 30082419
[TBL] [Abstract][Full Text] [Related]
3. Gene Therapy for Angelman Syndrome: Contemporary Approaches and Future Endeavors.
Tsagkaris C; Papakosta V; Miranda AV; Zacharopoulou L; Danilchenko V; Matiashova L; Dhar A
Curr Gene Ther; 2020; 19(6):359-366. PubMed ID: 31914913
[TBL] [Abstract][Full Text] [Related]
4. Understanding the pathogenesis of Angelman syndrome through animal models.
Jana NR
Neural Plast; 2012; 2012():710943. PubMed ID: 22830052
[TBL] [Abstract][Full Text] [Related]
5. Potential therapeutic approaches for Angelman syndrome.
Bi X; Sun J; Ji AX; Baudry M
Expert Opin Ther Targets; 2016; 20(5):601-13. PubMed ID: 26558806
[TBL] [Abstract][Full Text] [Related]
6. HAP1 is an in vivo UBE3A target that augments autophagy in a mouse model of Angelman syndrome.
Wang T; Wang J; Wang J; Mao L; Tang B; Vanderklish PW; Liao X; Xiong ZQ; Liao L
Neurobiol Dis; 2019 Dec; 132():104585. PubMed ID: 31445164
[TBL] [Abstract][Full Text] [Related]
7. Assessing the requirements of prenatal UBE3A expression for rescue of behavioral phenotypes in a mouse model for Angelman syndrome.
Sonzogni M; Zhai P; Mientjes EJ; van Woerden GM; Elgersma Y
Mol Autism; 2020 Sep; 11(1):70. PubMed ID: 32948244
[TBL] [Abstract][Full Text] [Related]
8. JNK signaling activation in the Ube3a maternal deficient mouse model: its specific inhibition prevents post-synaptic protein-enriched fraction alterations and cognitive deficits in Angelman Syndrome model.
Musi CA; Agrò G; Buccarello L; Camuso S; Borsello T
Neurobiol Dis; 2020 Jul; 140():104812. PubMed ID: 32087286
[TBL] [Abstract][Full Text] [Related]
9. Altered ultrasonic vocalization and impaired learning and memory in Angelman syndrome mouse model with a large maternal deletion from Ube3a to Gabrb3.
Jiang YH; Pan Y; Zhu L; Landa L; Yoo J; Spencer C; Lorenzo I; Brilliant M; Noebels J; Beaudet AL
PLoS One; 2010 Aug; 5(8):e12278. PubMed ID: 20808828
[TBL] [Abstract][Full Text] [Related]
10. Antisense oligonucleotide therapy rescues disturbed brain rhythms and sleep in juvenile and adult mouse models of Angelman syndrome.
Lee D; Chen W; Kaku HN; Zhuo X; Chao ES; Soriano A; Kuncheria A; Flores S; Kim JH; Rivera A; Rigo F; Jafar-Nejad P; Beaudet AL; Caudill MS; Xue M
Elife; 2023 Jan; 12():. PubMed ID: 36594817
[No Abstract] [Full Text] [Related]
11. Towards a therapy for Angelman syndrome by targeting a long non-coding RNA.
Meng L; Ward AJ; Chun S; Bennett CF; Beaudet AL; Rigo F
Nature; 2015 Feb; 518(7539):409-12. PubMed ID: 25470045
[TBL] [Abstract][Full Text] [Related]
12. Ube3a reinstatement identifies distinct developmental windows in a murine Angelman syndrome model.
Silva-Santos S; van Woerden GM; Bruinsma CF; Mientjes E; Jolfaei MA; Distel B; Kushner SA; Elgersma Y
J Clin Invest; 2015 May; 125(5):2069-76. PubMed ID: 25866966
[TBL] [Abstract][Full Text] [Related]
13. Ube3a reinstatement mitigates epileptogenesis in Angelman syndrome model mice.
Gu B; Carstens KE; Judson MC; Dalton KA; Rougié M; Clark EP; Dudek SM; Philpot BD
J Clin Invest; 2019 Jan; 129(1):163-168. PubMed ID: 30352049
[TBL] [Abstract][Full Text] [Related]
14. Truncation of Ube3a-ATS unsilences paternal Ube3a and ameliorates behavioral defects in the Angelman syndrome mouse model.
Meng L; Person RE; Huang W; Zhu PJ; Costa-Mattioli M; Beaudet AL
PLoS Genet; 2013; 9(12):e1004039. PubMed ID: 24385930
[TBL] [Abstract][Full Text] [Related]
15. UBE3A regulates the transcription of IRF, an antiviral immunity.
Furumai R; Tamada K; Liu X; Takumi T
Hum Mol Genet; 2019 Jun; 28(12):1947-1958. PubMed ID: 30690483
[TBL] [Abstract][Full Text] [Related]
16. Characterization and structure-activity relationships of indenoisoquinoline-derived topoisomerase I inhibitors in unsilencing the dormant
Lee HM; Clark EP; Kuijer MB; Cushman M; Pommier Y; Philpot BD
Mol Autism; 2018; 9():45. PubMed ID: 30140420
[TBL] [Abstract][Full Text] [Related]
17. Genome-wide gene expression profiling of the Angelman syndrome mice with Ube3a mutation.
Low D; Chen KS
Eur J Hum Genet; 2010 Nov; 18(11):1228-35. PubMed ID: 20571502
[TBL] [Abstract][Full Text] [Related]
18. Angelman Syndrome: From Mouse Models to Therapy.
Rotaru DC; Mientjes EJ; Elgersma Y
Neuroscience; 2020 Oct; 445():172-189. PubMed ID: 32088294
[TBL] [Abstract][Full Text] [Related]
19. The Angelman syndrome ubiquitin ligase localizes to the synapse and nucleus, and maternal deficiency results in abnormal dendritic spine morphology.
Dindot SV; Antalffy BA; Bhattacharjee MB; Beaudet AL
Hum Mol Genet; 2008 Jan; 17(1):111-8. PubMed ID: 17940072
[TBL] [Abstract][Full Text] [Related]
20. Ube3a is required for experience-dependent maturation of the neocortex.
Yashiro K; Riday TT; Condon KH; Roberts AC; Bernardo DR; Prakash R; Weinberg RJ; Ehlers MD; Philpot BD
Nat Neurosci; 2009 Jun; 12(6):777-83. PubMed ID: 19430469
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
